Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 14 Leukemia, Myeloid, Acute 8 Triple Negative Breast Neoplasms 3 Leukemia 3 Thrombocythemia, Essential 1 Primary Myelofibrosis 1 Primary Breast Cancer 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms 1 Neoplasm, Residual 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid 1 HER2-negative Breast Cancer 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1 Anemia, Refractory, with Excess of Blasts 1

Interventions

pembrolizumab 180 Gemcitabine 168 Paclitaxel 150 Carboplatin 134 Bevacizumab 126 Cisplatin 113 Docetaxel 112 Cyclophosphamide 109 Exercise 97 Nivolumab 92 Fluorouracil 88 Capecitabine 85 Dexamethasone 81 Irinotecan 74 Radiotherapy 68 Oxaliplatin 68 Pemetrexed 66 Standard of Care 64 Leucovorin 63 Cetuximab 59 Sorafenib 53 Erlotinib Hydrochloride 53 Drug Therapy 53 Blood Specimen Collection 52 Doxorubicin 50 trametinib 47 atezolizumab 47 Ipilimumab 47 Albumin-Bound Paclitaxel 44 130-nm albumin-bound paclitaxel 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms × Anthracyclines × Clear all

NCT04109066 2025-01-08

CheckMate 7FL

Bristol-Myers Squibb

Phase 3 Completed

521 enrolled 17 charts

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡